Are you aware of the latest data on CAR T-cell therapy in myeloma and the implications for our patients? Read my thoughts on this emerging treatment strategy and how I am using these agents in my practice.
What do you tell your patients who are about to receive CAR T-cell treatment? Here are the things I talk about when counseling these patients.
New clinical data are emerging on combining CAR T-cell therapy with checkpoint inhibitors. Here’s my take on the potential of this strategy to improve outcomes in patients who relapsed or never responded to CAR T-cell monotherapy.
A multidisciplinary team approach is vital to managing acute and long-term toxicities related to CAR T-cell therapy. Read my thoughts on the important roles of clinical and staff pharmacists in toxicity prevention, identification, and care for patients receiving these cutting-edge cellular therapies.
CAR T-cell therapy was one of the hottest topics at the 2019 ASH annual meeting. In this commentary, Michael R. Bishop, MD, provides his thoughts on key studies on this topic from the meeting.
Emerging data and clinical experience support offering CAR T-cell therapies to patients who would have been ineligible for registrational trials. How can we optimize our real-world patients to experience the best outcomes with these potentially curative therapies?
Review expert insights on incorporating CAR T-cell therapies into management of hematologic malignancies, including optimization of real-world patients, multidisciplinary management of toxicities, patient and caregiver education, and emerging data on the most promising investigational strategies.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.